Brookline Capital Markets Comments on HURA FY2030 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Investment analysts at Brookline Capital Markets decreased their FY2030 earnings estimates for TuHURA Biosciences in a research note issued to investors on Wednesday, May 27th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn $0.43 per share for the year, down from their previous forecast of $0.52. The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.51) per share.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Several other research firms also recently issued reports on HURA. Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Citigroup began coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating for the company. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They set a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Price Performance

NASDAQ HURA opened at $2.35 on Friday. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.90. The company has a market capitalization of $149.65 million, a PE ratio of -3.85 and a beta of -0.01. The company has a fifty day moving average of $2.25 and a two-hundred day moving average of $1.60.

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds have recently added to or reduced their stakes in HURA. Geode Capital Management LLC lifted its position in TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after purchasing an additional 307,260 shares during the period. Cetera Investment Advisers purchased a new stake in shares of TuHURA Biosciences during the 1st quarter worth approximately $251,000. WealthShield Partners LLC purchased a new stake in shares of TuHURA Biosciences during the 1st quarter worth approximately $164,000. Deutsche Bank AG boosted its stake in shares of TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after acquiring an additional 54,051 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $97,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.